<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02202473</url>
  </required_header>
  <id_info>
    <org_study_id>Oxymatrine</org_study_id>
    <nct_id>NCT02202473</nct_id>
  </id_info>
  <brief_title>Oxymatrine Plus Lamivudine Combination Therapy Versus Lamivudine Monotherapy for Chronic Hepatitis B Infected Subjects</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southeast University, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cttq</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Southeast University, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of Oxymatrine plus Lamivudine
      Combination Therapy and whether it could lower the incidence of Lamivudine long-term
      resistance compared to Lamivudine Monotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Group A (Lamivudine Monotherapy): Lamivudine (Manufacturer: GlaxoSmithKline) 100mg po, qd.

      Group B (Oxymatrine + Lamivudine Combination Therapy): Lamivudine (Manufacturer:
      GlaxoSmithKline) 100mg po, qd; oxymatrine Capsules (Chia Tai Tianqing Pharmaceutical Group
      Co., Ltd) 200 mg, po, tid.

      Total subjects: 200, 100 patients randomized in each group.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of Hepatitis B virus DNA titer compared to Baseline Hepatitis B virus DNA titer every 3 months for 18 months</measure>
    <time_frame>1, 3, 6, 12, 15, 18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hepatitis B virus resistance loci</measure>
    <time_frame>1, 3, 6, 12, 15, 18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">192</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Lamivudine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lamivudine (Manufacturer: GlaxoSmithKline) 100mg po, qd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lamivudine+Oxymatrine Capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lamivudine (Manufacturer: GlaxoSmithKline) 100mg po, qd; oxymatrine Capsules (Chia Tai Tianqing Pharmaceutical Group Co., Ltd) 200 mg, po, tid.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
    <arm_group_label>Lamivudine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine+Oxymatrine Capsules</intervention_name>
    <arm_group_label>Lamivudine+Oxymatrine Capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 to 60 years old.

          2. Subjects diagnosed as chronic hepatitis B according to 2000 Xi'an Conference
             Guidelines: Management of chronic hepatitis B. Alanine transaminase &gt;80 IU/L, total
             bilirubin&lt;85.5 mmol/L, Hepatitis B virus DNA &gt;1×10^5copies/mL; haven't been treated
             with antiviral therapy within 6 months before screening.

          3. able to give written informed consent and to comply with the study protocol.

          4. Women of childbearing potential (WOCBP) must be using an adequate method of
             contraception to avoid pregnancy throughout the study.

        Exclusion Criteria:

          1. Evidence of hepatocellular carcinoma

          2. Clinical symptoms of Decompensated liver disease at screening, including but not
             limited to: Serum bilirubin≥1.5 x upper limit of normal, prothrombin time of greater
             than 2 seconds prolonged, a serum albumin&lt; 32g/L, or a history of ascites, variceal
             bleeding, or hepatic encephalopathy;

          3. Alanine transaminase&gt;10 x upper limit of normal at screening or history of Transient
             hepatic decompensation caused by acute exacerbation;

          4. hemoglobin&lt; 10g/dL, Neutrophil count&lt;1.5 × 10^9/L, platelet count&lt; 80 × 10^9/L;

          5. Evidence of active liver disease from other causes, including co-infection with
             hepatitis A virus, co-infection with hepatitis E virus, co-infection with hepatitis C
             virus, co-infection with hepatitis D virus, co-infection with HIV, autoimmune
             hepatitis (antinuclear antibody titer&gt; 1:100);

          6. Use of immunosuppressors, immunomodulators (including interferon or thymosin) within 6
             months before enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>the second hospital of Nanjing</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Lu FM, Zhuang H. Management of hepatitis B in China. Chin Med J (Engl). 2009 Jan 5;122(1):3-4.</citation>
    <PMID>19187608</PMID>
  </reference>
  <reference>
    <citation>Yuen MF, Fung J, Wong DK, Lai CL. Prevention and management of drug resistance for antihepatitis B treatment. Lancet Infect Dis. 2009 Apr;9(4):256-64. doi: 10.1016/S1473-3099(09)70056-8. Review.</citation>
    <PMID>19324298</PMID>
  </reference>
  <reference>
    <citation>Wang YP, Zhao W, Xue R, Zhou ZX, Liu F, Han YX, Ren G, Peng ZG, Cen S, Chen HS, Li YH, Jiang JD. Oxymatrine inhibits hepatitis B infection with an advantage of overcoming drug-resistance. Antiviral Res. 2011 Mar;89(3):227-31. doi: 10.1016/j.antiviral.2011.01.005. Epub 2011 Jan 28.</citation>
    <PMID>21277330</PMID>
  </reference>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2014</study_first_submitted>
  <study_first_submitted_qc>July 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2014</study_first_posted>
  <last_update_submitted>July 24, 2014</last_update_submitted>
  <last_update_submitted_qc>July 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Southeast University, China</investigator_affiliation>
    <investigator_full_name>Wei Zhao</investigator_full_name>
    <investigator_title>director of the hospital</investigator_title>
  </responsible_party>
  <keyword>Oxymatrine Capsules, lamivudine, chronic Hepatitis B</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Oxymatrine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

